Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-03-01
2005-03-01
Winkler, Ulrike (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S188100, C424S204100, C514S012200, C514S045000, C514S049000, C514S050000, C530S300000, C530S324000, C530S325000
Reexamination Certificate
active
06861059
ABSTRACT:
Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.
REFERENCES:
patent: 4950652 (1990-08-01), Carter
patent: 5077280 (1991-12-01), Sommadossi et al.
patent: 5141867 (1992-08-01), Ivanoff et al.
patent: 5393883 (1995-02-01), Blumenhopf et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6228983 (2001-05-01), Barney et al.
patent: 6440656 (2002-08-01), Bolognesi et al.
patent: 6479055 (2002-11-01), Bolognesi et al.
patent: WO 9007119 (1990-06-01), None
patent: WO 9109872 (1991-07-01), None
patent: WO 9222654 (1992-12-01), None
U.S. Appl. No. 08/264,531, filed Jun. 23, 1994, Wild et al.
Najera et al., 1995, “pol Gene Quasispecies of Human Immunodeficiency Virus Mutations Associated with Drug Resistance in Virus from Patients Undergoing No Drug Therapy”, J Virol 69:23-31.
Ho et al., 1995, “Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection”, Nature 373:123-126.
Wei et al., 1995, “Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection”, Nature 373:117-122.
Matthews et al., 1994, “Structural Rearrangements in the Transmembrane Glycoprotein After Receptor Binding”, Immunol Rev 140:93-104.
Wild et al., 1994, “Peptides Corresponding to a Predicative α-Helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection”, Proc Natl Acad Sci USA 91:9770-9774.
Lambert et al., 1993, “Synergistic Drug Interactions of an HIV-1 Protease Inhibitor with AZT in Different In Vitro Models of HIV-1 Infection”, Antiviral Research 21:327-342.
Wild et al., 1992, “A Synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure and Viral Inhibition”, Proc Natl Acad Sci USA 89:10537-10541.
Mitsuya et al., 1990, “Molecular Targets for AIDS Therapy”, Science 249:1533-1544.
Mitsuya et al., 1991, “Targeted Therapy of Human Immunodeficiency Virus-Related Disease”, FASEB J 5:2369-2381.
Schooley et al., 1990, “Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex”, 1990, Ann Int Med 112:247-253.
Pritchard and Shipman, 1990, “A Three-Dimensional Model to Analyze Drug-Drug Interactions”, Antiviral Research 14:181-206.
Erickson et al., 1990, “Design, Activity, and 2.8 Å Crystal Structure of a C2Symmetric Inhibitor Complexed to HIV-1 Protease”, Science 249:527-533.
Larder et al., 1989, “HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy”, Science 243:1731-1734.
Hammerwskjold and Rekosh, 1989, “The Molecular Biology of the Human Immunodeficiency Virus”, Biochem Biophys Acta 989:269-280.
Willey et al., 1988, “In Vitro Mutagenesis Identifies a Region Within the Envelope Gene of the Human Immunodeficiency Virus That Is Critical for Infectivity”, J Virol 62:139-147.
Pottage et al., 1988, “Treatment of Human Immunodeficiency Virus-Related Thrombocytopenia with Zidovudine”, JAMA 260:3045-3048.
Varmus, 1988, “Retroviruses”, Science 240:1427-1439.
Smith et al., “Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen”, Science 238:1704-1707.
Mitsuya and Broder, 1987, “Strategies for Antiviral Therapy in AIDS”, Nature 325:773-778.
Matthews et al., 1987, “Interaction Between the Human T-Cell Lymphotropic Virus Type IIIBEnvelope Glycoprotein gp120 and the Surface Antigen CD4: Role of Carbohydrate in Binding and Cell Fusion”, Proc Natl Acad Sci USA 84:5424-5428.
Fischl et al., 1987, “The Efficacy of Azidothymidine (AZT) In The Treatment of Patients with AIDS and AIDS-Related Complex”, N Engl J Med 317:185-191.
McDougal et al., 1986, “Binding of HTLV-III/LAV to T4+T Cells by a Complex of the 110K Viral Protein and the T4 Molecule”, Science 231:382-385.
Maddon et al., 1986, “The T4 Gene Encodes the AIDS Virus Receptor and Is Expressed in the Immune System and the Brain”, Cell 47:333-348.
Pringle et al., 1985, “A Survey of Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Neutralising and Immunoprecipitating Antibodies in Relation to Paget Disease”, J Medical Virology 17:377-386.
Barin et al., 1985, “Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients”, Science 228:1094-1096.
Gallo et al., 1984, “Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS”, Science 224:500-503.
Chou and Talalay, 1984, “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”, Adv Enzyme Regul 22:27-55.
Dalgleish et al., 1984, “The CD4 (T4) Antigen is an Essential Component of the Receptor from the AIDS Retrovirus”, Nature 312:763-768.
Barre-Sinossi et al., 1983, “Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)”, Science 220:868-871.
Goff et al., 1981, “Isolation and Properties of Moloney Murine Leukemia Virus Mutants: Use of a Rapid Assay for Release of Virion Reverse Transcriptase”, J Virol 38:239-248.
Fox, “No Winners Against HIV”, Bio/Technology:12:128.
Kovacs et al., 1989, “Combined Zidovudine and Interferon-a Therapy in patients with Kaposi sarcoma and acquired immunodeficiency syndrome (AIDS)” Ann. Inter. Med. 111: 280-287.
Hartshorn et al., 1987, “Synergistic Inhibition of Human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon”, Antimicrob. Agents and Chemo. 31: 168-172.
Perno et al., 1988, “Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides” J Exp Med. 168:1111-1125.
Boyle, et al., 1995, “The Human HIV/Peripheral Blood Lymphocyte (PBL)-SCID Mouse. A Modified Human PBL-SCID Model for the Study of HIV Pathogenesis and Therapy”, J. Immunol. 154:6612-23.
Church et al., 2001, “Safety and Antiviral Activity of Chronic Subcutaneous Administration of T-20 in HIV-1-infected Children”, 8thConference on Retroviruses and Opportunistic Infections. Chicago, IL, Feb. 4-8, 2001.
Deeks, 2001, “Nonnucleoside Reverse Transcriptase Inhibitor Resistance”, JAIDS 26: S25-S33.
Greer, 1001, “Structural Basis Found for NNRTI Cross-Resistance”, Aids Weekly Aug. 13, 2001.
Hertogs et al., 2000, “Phenotypic and Genotypic Analysis of Clinical HIV-1 Isolates Reveals Extensive Protease Inhibitor Cross-Resistance: a Survey of Over 6000 Samples”, AIDS 14:1203-1210.
Kilby et al., 1998, “Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry,” Nature Med. 4:1302-1307.
Lalezari et al., 1999, “Sixteen Week Analysis of Heavily Pre-Treated Patients Receiving T-20 as a Component of Multi-Drug Therapy”, 39th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California, Sep. 26-29, 1999.
Lambert et al., 1996, “T20, a Peptide-
Johnson M. Ross
Lambert Dennis Michael
Jones Day
Nelson Bud
Trimeris, Inc.
Winkler Ulrike
LandOfFree
Methods and compositions for treatment of HIV-1 infection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of HIV-1 infection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of HIV-1 infection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3429002